It has been over a year since the pandemic began and the market crashes and since then the market has been soaring. In the last few months, the roll out of the COVID-19 vaccine has resulted in a relaxing of regulations across the board and more Americans resuming a semi-normal life outside of quarantine. Although the pandemic is not completely over, especially in other countries, it is improving greatly in the US and the economic projections based on the past indicate a positive trend to continue. Empirically, the annual economic return on vaccinations has been estimated by the Global Alliance for Vaccines and Immunizations (GAVI) to be between 12% and 18% – verifying the economy may have room to grow. Of course, this is no guarantee, but the signs look positive.
This progress could be accelerated further by Pfizer’s latest announcement. Just yesterday, Pfizer announced that they are working on the early-stage clinical trial of a new antiviral therapy for COVID-19. CEO of Pfizer, Albert Bourla, said that If clinical trials go well and the Food and Drug Administration approves it, the drug could be distributed across the U.S. by the end of the year. On top of this, Health experts believe the drug could be revolutionary because people newly infected with the virus could use it outside of hospitals. Researchers also hope the medication will keep the disease from progressing and prevent further hospital visits.
What do you think about this new drug? And do you think it will pass the FDA?
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.